Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.51 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518799 | 0.90 | GPR119 (0.52) | GPR119GRM3ABL1RIN1TGFBR1 | |
| SCHEMBL4516799 | 0.90 | ABL1 (0.58) | GPR119ABL1RIN1L3MBTL1TGFBR1 | |
| SCHEMBL4520801 | 0.89 | ABL1 (0.59) | GPR119ABL1RIN1L3MBTL1TGFBR1 | |
| SCHEMBL4516324 | 0.87 | GPR119 (0.54) | GPR119ABL1RIN1TGFBR1MEN1 | |
| SCHEMBL4516328 | 0.87 | GPR119 (0.54) | GPR119ABL1RIN1TGFBR1MEN1 | |
| SCHEMBL4524071 | 0.86 | GPR119 (0.51) | GPR119ABL1RIN1TGFBR1MEN1 | |
| SCHEMBL4511902 | 0.85 | GPR119 (0.56) | GPR119ABL1RIN1TGFBR1MEN1 | |
| SCHEMBL4504053 | 0.83 | GPR119 (0.60) | GPR119TGFBR1MEN1KMT2A | |
| SCHEMBL4515782 | 0.82 | GPR119 (0.74) | GPR119TGFBR1MEN1KMT2A | |
| SCHEMBL7366692 | 0.81 | GPR119 (0.59) | GPR119TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | GPR119 1/4885GRM3 116/4885ABL1 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.